Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Saturday, August 13, 2022 · 585,948,913 Articles · 3+ Million Readers

Global Wilson’s Disease Treatment Market to Surpass US$ 854.5 Million by 2030, Says Coherent Market Insights (CMI)

/EIN News/ -- Seattle, June 27, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global Wilson’s disease treatment market is estimated to be valued at US$ 527.0 million in 2022 and is expected to exhibit a CAGR of 6.2% during the forecast period (2022-2030).

Key Trends and Analysis of the Global Wilson’s Disease Market:

Major players in market are adopting inorganic growth strategies such as partnership Gene Therapy Company to start a joint project regarding development of Vivet’s VTX-801 programme. Vivet’s VTX-801 programme aims to treat the rare liver disorder such as Wilson’s disease. Pfizer made an investment of its share of around US$ 51 mn for the equity stake and may additionally pay up to $635.8m, inclusive of option exercise fee and subject to potential regulatory, commercial and clinical milestones. As part of the partnership, Pfizer has obtained a 15% stake in Vivet Therapeutics, along with an exclusive option to buy all outstanding shares.

Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/526

Key Market Takeaways:

Global Wilson’s disease treatment market is expected to exhibit a CAGR of 6.2% during the forecast period, due to increasing approval of Wilson’s disease treatment drugs by regulatory authority. For instance, in May 2022 Food and Drug Administration (FDA) approved Cuvrior (trientine tetrahydrochloride) to treat Wilson’s disease in adults. Cuvrior (trientine tetrahydrochloride) is the first medication approved for Wilson’s diseaseication segment is expected to expand at a significant CAGR of 6.0% over the forecast period. This is mainly attributed to increasing adoption of D-penicillamine, owing to its wide availability and high efficacy of treatment.

Among regions, North America is estimated to account for largest share in the global Wilson’s disease treatment market over the forecast period. This is mainly attributed to increasing launches of generic drug for the treatment of Wilson’s disease. For instance, in 2021, Lupin Limited, has launched the Penicillamine tablets for the treatment of Wilson’s disease in the U.S.

Competitive Landscape:

Key players operating in the global Wilson’s disease treatment market include Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/526

Market Segmentation:

  • Global Wilson’s Disease Treatment Market, By Treatment Type:
    • Medications
      • D-Penicillamine
      • Trientine
      • Zinc
      • Tetrathiomolybdate
    • Others
  • Global Wilson’s Disease Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Government Bodies
  • Global Wilson’s Disease Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Reports:

Colombia, Chile and Peru Wilson’s Disease Treatment Market, by Drugs (D-Penicillamine, Trientine, and Zinc Acetate), by Distribution Channel (Hospital Pharmacies and Government Distribution Channels), and by Country (Colombia, Chile, and Peru) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

Peripheral Neuropathy Treatment Market, by Indication (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and others), by Treatment (Pharmacological Therapies(Pain Relievers, Anti-seizure Medications, Antidepressants) and Non-pharmacological Therapies (Transcutaneous Electrical Nerve Stimulation, Plasma Exchange, and Others), by End User (Hospital, Ambulatory Centers, and Others), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Follow Us: LinkedInTwitter


                    Mr. Shah
                    Senior Client Partner – Business Development
                    Coherent Market Insights
                    
                    Phone:
                    US: +1-206-701-6702
                    UK: +44-020-8133-4027
                    Japan: +81-050-5539-1737
                    India: +91-848-285-0837
                    Email: sales@coherentmarketinsights.com
                    Website: https://www.coherentmarketinsights.com

Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release